Abstract
This study was designed to compare effectiveness and safety of warfarin, direct thrombin inhibitor dabigatran, Xa factor inhibitors rivaroxaban and apixaban used to prevent stroke in 280 elderly patients in patients with age-specific non-valvular atrial fibrillation. The treatment of patients aged 65-74 and 75-80 yearsfor 2 years with dab itragan (110 mg b.i.d), apixaban (5 mg b. i. d), and rivaroxaban (20 mg once daily) prevented stroke as effectively as warfarin therapy but less frequently caused severe intracranial hemorrhage. It is concluded that these new anticoagulants can be used as alternative medication for antithrombotic therapy of elderly patients with age-specific non-valvular atrialfibrillation.
Publication types
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
Age Factors
-
Aged
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / drug therapy*
-
Dabigatran* / administration & dosage
-
Dabigatran* / adverse effects
-
Drug Monitoring / methods
-
Female
-
Humans
-
International Normalized Ratio / methods
-
Intracranial Hemorrhages* / chemically induced
-
Intracranial Hemorrhages* / prevention & control
-
Male
-
Middle Aged
-
Pyrazoles* / administration & dosage
-
Pyrazoles* / adverse effects
-
Pyridones* / administration & dosage
-
Pyridones* / adverse effects
-
Rivaroxaban* / administration & dosage
-
Rivaroxaban* / adverse effects
-
Stroke / etiology
-
Stroke / prevention & control*
-
Treatment Outcome
-
Warfarin* / administration & dosage
-
Warfarin* / adverse effects
Substances
-
Anticoagulants
-
Pyrazoles
-
Pyridones
-
apixaban
-
Warfarin
-
Rivaroxaban
-
Dabigatran